The IMPACT BE Program was developed in close collaboration with a prestigious team of clinician advisors who are dedicated to improving airway clearance education in the clinical setting. This Advisory Team provided input on the program strategy and toolset during the initial concepting phase and at key milestone points throughout the program development process.
Bronchiectasis (bron-kee-eck-tuh-sis) is a condition affecting the airways in the lungs that causes cough, increased mucus production, and recurrent lung infections. The symptoms are caused by abnormal widening of the airways of the lung, also known as bronchi. The cells lining the airways become inflamed and swollen. These damaged airways can no longer effectively clear mucus and bacteria from the lung. This can lead to flare-ups of cough, mucus production, and shortness of breath.
Bronchiectasis is caused by one or more infections introduced into the lungs. People with bronchiectasis are more likely to get lung infections. Each lung infection can make the bronchiectasis worse. Therefore, early diagnosis and treatment of bronchiectasis is very important.
Cystic fibrosis, also known as CF or sixty-five (65) roses, is an inherited genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, causing the CFTR protein to malfunction.
When the protein is not working correctly, it’s unable to help move chloride to the cell surface. Without the chloride to attract water to the cell surface, the mucus in various organs becomes thick and sticky. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas.
Although cystic fibrosis requires daily care and treatments, people with cystic fibrosis are usually able to attend school and work. Improvements in screening and treatment options have given people with cystic fibrosis the ability to live into their mid- to late 30s, on average, and some are living into their 40s and 50s.